NCT07492641
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07492641
Title BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease (KANDELA-302)
Acronym KANDELA-302
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors BeOne Medicines
Indications
Therapies
Age Groups: senior | adult
Covered Countries AUS


No variant requirements are available.